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This article is a commentary on Song et al., of this issue. To view this paper visit http://dx.doi.org/10.1111/ j. 1476-5381.2011.01411.x Abbreviations PPARG, gene encoding peroxisome proliferator-activated receptor-g; PPARg, peroxisome proliferator-activated receptor-g; TCM, traditional Chinese medicines Diabetic retinopathy is a severe microvascular complication of diabetes mellitus, which occurs within in the first two decades from diabetes onset. It affects the retina of almost all patients with type I diabetes and about 60% of those with type II diabetes. Changes in the retinal biochemistry and physiology appear long before clinically evident disease is observed. Furthermore, characteristic symptoms, such as macular oedema, vitreous haemorrhage, traction retinal detachment, exudates and intraocular pathological neovascularization, are observed in nearly all patients, even with variable severity (Silva et al., 2010) . All the mechanisms underlying diabetic retinopathy, as for other vascular complications of diabetes mellitus, have not yet been fully elucidated. However, in the last years the complex relationship existing among the most relevant contributors to the onset and progression of diabetic retinopathy, such as advanced glycation end products, oxidative stress, inflammation and angiogenesis, have been intensively investigated and, particularly, by whole-genome expression analyses in cells and animal models (Brucklacher et al., 2008) . Moreover, gene expression profiling of altered genes in animal models of diabetic retinopathy has provided novel intriguing molecular targets to be validated through focused studies, which can be useful to improve our knowledge of retinal physiology and pathophysiology, in conditions such as diabetes mellitus. The data from this gene expression profiling reinforce the hypothesis of a feed-forward cycle of chronic inflammation and neurodegeneration (Brucklacher et al., 2008) .
In the light of the complex interactions among the different molecular pathways in the retinal (different subtypes of retinal cells) and endothelial cells, it is not easy to fully exploit the real contribution of each factor to the pathogenesis of diabetic retinopathy, and particularly to address the potential targets for a drug-based therapeutic approach.
However, recent studies on patients with diabetic retinopathy and appropriate animal models have shown that the gene, PPARG, encoding a member of the nuclear receptor superfamily, the peroxisome proliferator-activated receptor-g (PPARg), may represent a valuable target to rescue -or ameliorate -the endothelial and retinal damage due to highglucose-induced prolonged inflammation (Gerry and Pascual, 2008) .
The protein PPARg is a ligand-inducible pleiotropic transcription factor, which has different isoforms characterized by distinct expression patterns and functions (Sabatino et al., 2005) . This transcription factor is able to modulate its transcriptional activity through conformational changes and the binding to different -temporally and spatially regulatedcofactors (Perissi and Rosenfeld, 2005) . Furthermore, noncanonical mechanisms, such as SUMOylation of PPARg ligand-binding domains, are responsible for the repression of inflammatory response genes controlled by NF-kB (Pascual et al., 2005) . Nevertheless, its activation by natural or synthetic ligands may also provide undesirable and often unexplained side effects, which are directly linked to its functioning as regulator of gene expression with (potentially) opposite effects in different cells, tissues or organs, according to the specific surrounding environment (Costa et al., 2010) .
Moreover, key roles for PPARg in glucose metabolism, angiogenesis and inflammation pathways, the growing evidence of the anti-inflammatory, -oxidative and -proliferative effects of its synthetic and natural ligands (Knouff and Auwerx, 2004) , and also the association of nucleotide variants in the PPARG gene with diabetes mellitus and with diabetic retinopathy (Malecki et al., 2008; Costa et al., 2009 ), all strongly suggest that this nuclear receptor should be a primary target in treatment of diabetic retinopathy.
In this issue of the BJP, Tom Huang's group (Song et al., 2011) highlight, for the first time, in a comprehensive review article, the key role of PPARG in diabetic retinopathy-related disorders. As the pathogenesis of diabetic retinopathy involves different complementary molecular mechanisms, the authors describe in detail the complex connections between the pathways involved and the related protein effectors, citing most of the relevant work in the field. In addition, the PPARg-mediated inhibition of diabetes-induced retinal leukostasis and leakage, and the role of this nuclear receptor within apoptosis, inflammation and angiogenesis pathways, are also clearly elucidated. Moreover, Song et al. provide a full description of PPARg ligands derived from medicinal plants and they explain the potential of using these compounds in the modulation of diabetic retinopathy-related pathogenesis. Indeed, in the last years, there has been a growing interest in this area and some important results have emerged in the use of alternative therapies, such as traditional Chinese medicines (TCM) and the therapeutic use of natural compounds, especially those derived from plants.
Novel treatments, derived from natural sources, possibly in combination with commonly used 'standard therapies', may help to provide major improvements in efficacy and in safety profiles for these treatments and/or the prevention of diabetes mellitus and its related microvascular and macrovascular complications, including diabetic retinopathy. However, as underlined by Song et al., there are few and not yet conclusive, studies on the efficacy and safety of treatments based on natural and herbal medicines, although their use in medical practice has become wider, in the last few years. Furthermore, although there are many individual examples of the successful clinical use of these non-traditional herbal formulations, to date no registered clinical trials for treatment of diabetic retinopathy are currently active (except 'NCT00904592' for TCM, http://www.clinicaltrials.gov). Systematic analyses, from both clinical and basic research, are still in their infancy and much more effort is needed in this direction. Indeed, the direct effects of the phytochemical components -contained in these herbal formulations -on the molecular pathways of cells and/or animal models have not yet been systematically addressed, thus impairing, or at least putting in doubt, their potentially scientific validity. Nonetheless, very recently, systematic approaches -mostly relying on hybridization-based technology -have been used for elucidating the molecular targets of TCM and their mechanisms of action (Kang et al., 2005; Wang et al., 2008; Wen et al., 2011) . These findings have indicated that the study of gene expression changes may represent a powerful tool to understand the mechanisms of actions for several natural compounds in different cell models. By combining together -and integrating -genomics, proteomics and metabolomics data, putative novel biomarkers are likely to be identified, allowing also the assessment of the quality of herbal formulations (Wen et al., 2011) . Moreover, a thorough and systematic examination of changes in gene expression induced by herbal formulations is likely to be a crucial task.
Finally, extensive preclinical and clinical trials, driven by a detailed and proven knowledge of the molecular targets, are needed to establish the efficacy and to prove the safety of many commercially available natural medicines, possibly in combination with standard therapy, for the treatment of diabetic retinopathy and for other vascular complications of diabetes.
